Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year High After Strong Earnings

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) hit a new 52-week high during trading on Tuesday after the company announced better than expected quarterly earnings. The stock traded as high as $39.37 and last traded at $36.31, with a volume of 52892 shares traded. The stock had previously closed at $34.70.

The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The business had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. During the same quarter in the prior year, the company earned ($0.29) earnings per share. The firm’s quarterly revenue was up 14.2% compared to the same quarter last year.

Analysts Set New Price Targets

A number of brokerages have weighed in on SUPN. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SUPN. Sei Investments Co. grew its holdings in shares of Supernus Pharmaceuticals by 24.4% during the first quarter. Sei Investments Co. now owns 330,580 shares of the specialty pharmaceutical company’s stock valued at $11,276,000 after buying an additional 64,752 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Supernus Pharmaceuticals by 205.2% in the 1st quarter. Russell Investments Group Ltd. now owns 97,988 shares of the specialty pharmaceutical company’s stock worth $3,342,000 after purchasing an additional 65,880 shares in the last quarter. State Board of Administration of Florida Retirement System raised its stake in shares of Supernus Pharmaceuticals by 250.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 49,160 shares of the specialty pharmaceutical company’s stock worth $1,781,000 after purchasing an additional 35,137 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Supernus Pharmaceuticals by 26.4% during the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock valued at $45,077,000 after purchasing an additional 351,900 shares in the last quarter. Finally, Bank of Montreal Can boosted its position in shares of Supernus Pharmaceuticals by 1,508.0% during the second quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock valued at $3,287,000 after buying an additional 109,088 shares during the last quarter.

Supernus Pharmaceuticals Trading Up 0.1 %

The firm has a fifty day moving average of $33.02 and a 200 day moving average of $30.50. The company has a market capitalization of $1.91 billion, a P/E ratio of 386.00 and a beta of 0.86.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.